Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
English
Regional settings
Entity•Capital Com UK LimitedAuthorised and regulated by the Financial Conduct Authority (FCA)
Why Capital.com?
About us
Our history
Our offices
Leadership team
Client funds
How Capital.com makes money
Contact us
Terms and policies
Ways to trade
CFD trading
Spread betting
1X
Charges and fees
Professional
Margin Calls
Markets
Shares
Forex
Indices
Commodities
Trading platforms 
Web platform
Mobile apps
MT4
TradingView
Demo
Learn to trade
Essentials of trading
Risk-management guide
Market guides
Trading Strategies
Trading Psychology
Technical analysis
Market analysis
Help
My account

HomeMarketsSharesAcurx Pharmaceuticals, Inc.

Trade Acurx Pharmaceuticals, Inc. - ACXP CFD

SummaryHistorical Data
Trading Conditions
Spread0.09
Long position overnight fee
Long position overnight fee
Margin. Your investment
$1,000.00
Overnight fee
Charges from full value of position
-0.026179 %
(-$1.05)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

-0.026179%
Short position overnight fee
Short position overnight fee
Margin. Your investment
$1,000.00
Overnight fee
Charges from full value of position
0.003957 %
($0.16)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

0.003957%
Overnight fee time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin20
Stock exchangeUnited States of America
Commission on trade10%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close2.14
Open2.11
1-Year Change-26.74%
Day's Range2.06 - 2.26

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.